Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle View 
March 28, 2017Pernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
March 15, 2017Pernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March 28
February 23, 2017Pernix Therapeutics Prevails in Zohydro® ER ANDA Litigation
February 3, 2017Pernix Therapeutics Provides Update on Arbitration
January 6, 2017Pernix Therapeutics Appoints Ken Piña as General Counsel and Chief Compliance Officer
November 22, 2016Pernix Therapeutics Appoints New Board Member
November 10, 2016Pernix Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update
November 7, 2016Pernix Therapeutics Appoints Two Board Members
October 31, 2016Pernix Therapeutics to Report Third Quarter 2016 Financial Results on November 10, 2016
October 13, 2016Pernix Therapeutics Announces Reverse Stock Split and Corporate Governance Enhancements
September 28, 2016Pernix Therapeutics Announces Distribution of TREXIMET® 10/60 mg (sumatriptan 10mg and naproxen sodium 60 mg) Dose For Use in Pediatric Patients
September 16, 2016Marsha Stanton, Ph.D., RN, Pernix Therapeutics Executive Director of Medical and Government Affairs, Awarded Prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing®
September 14, 2016Pernix Therapeutics Announces the Issuance of Two New Orange Book Listed Patents for Zohydro® ER with BeadTek™
September 9, 2016Pernix Therapeutics Announces Significant Presence at PAINWeek 2016
August 11, 2016Pernix Therapeutics Reports Second Quarter 2016 Financial Results and Business Update
August 4, 2016Pernix Therapeutics to Report Second Quarter 2016 Financial Results on August 11, 2016
July 26, 2016Pernix Therapeutics Announces Reorganization of Senior Management Team
July 7, 2016Pernix Therapeutics Announces Restructuring  of Sales Force and Operations
June 16, 2016Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study
May 25, 2016Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro® ER with BeadTek™
May 11, 2016Pernix Therapeutics Announces CEO Transition
May 9, 2016Pernix Therapeutics Overcomes Challenge to Treximet® ‘183 Patent
May 5, 2016Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
April 28, 2016Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016